Theorem Clinical Research

Takeda

Clinicians, researchers and industry collaborate with the 100,000 Genomes Project

Friday, March 27, 2015 11:12 AM

Genomics England has announced a new collaboration as part of the 100,000 Genomes Project to accelerate the development of new diagnostics and treatments for patients. Ten pharma and biotech companies have come together to create the Genomics Expert Network for Enterprises (GENE) Consortium to oversee a year-long industry trial.

More... »

Quest Diagnostics

Takeda, ImmunoGen partner

Monday, March 23, 2015 03:38 PM

Takeda Pharmaceutical, a research-based global company headquartered in Osaka, Japan, has licensed exclusive rights to use ImmunoGen's ADC technology—including ImmunoGen's new DNA-acting IGN payload agents—to develop and commercialize targeted anticancer therapeutics to up to two undisclosed targets.

More... »


Novo Nordisk, Takeda, Servier, Celgene among top sponsors rated by investigative sites in new CenterWatch survey

Monday, March 2, 2015 08:00 AM

More than 1,900 global investigative sites rate the best biopharmaceutical companies with which to work in a new survey conducted by CenterWatch, a leading provider of global clinical trials information. The survey results were released today in the March issue of The CenterWatch Monthly newsletter.

More... »

The CenterWatch Monthly, March 2015

Monday, March 2, 2015 08:00 AM

Novo Nordisk, Takeda, ServierCelgene among top sponsors

More... »

20 life sciences, IT organizations invest in tranSMART Foundation

Thursday, January 15, 2015 12:55 PM

The tranSMART Foundation, a nonprofit organization headquartered in Wakefield, Mass., providing a global, open-source knowledge management platform for scientists to share pre-competitive translational research data, said 20 life sciences and technology organizations have made substantial commitments by joining its membership program.

More... »

Takeda renames Millennium as Takeda Oncology

Wednesday, December 10, 2014 01:10 PM

Takeda Pharmaceutical has announced its global oncology business unit, headquartered in Cambridge, Mass., now will be called Takeda Oncology. The creation of Takeda Oncology will improve the company's ability to meet the unique and urgent needs of cancer patients, their loved ones and health care providers worldwide. Takeda will sustain its long-standing entrepreneurial approach to oncology R&D, while expanding its global commercial network and resources as Takeda Oncology.

More... »

Report: Pharma is improving medicines access, but progress is uneven

Monday, November 17, 2014 02:30 PM

The world’s leading pharmaceutical companies are doing more to improve access to medicine in developing countries, with a raft of new initiatives, scale-ups and innovations over the last two years. However, the industry struggles to perform well in some practices that matter, according to the 2014 Access to Medicine Index, published by the Access to Medicine Foundation, a nonprofit organization based in the Netherlands that aims to advance access to medicine by encouraging the pharmaceutical industry to play a greater role in improving access to medicine in less developed countries.

More... »

BioMotiv, Takeda partner for medical innovation

Monday, September 29, 2014 01:06 PM

Takeda Pharmaceutical, a research-based global company headquartered in Osaka, Japan, has invested in BioMotiv, a therapeutic accelerator company associated with the Ohio-based Harrington Project for Discovery & Development, and they have partnered to identify and develop pioneering medical innovations.

More... »

FDA approves weight-management drug Contrave

Friday, September 12, 2014 12:49 PM

The FDA has approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.

More... »

Seven pharma companies offer deprioritized compounds for re-purposing

Wednesday, July 23, 2014 10:15 AM

U.K. researchers will be granted access to a ‘virtual library’ of deprioritized pharmaceutical compounds through a new partnership between the Medical Research Council (MRC) and seven global drug companies.

More... »


CWWeekly

March 23

Industry welcomes FDA draft guidance outlining the use of electronic Informed Consent for trials

Apple launches ResearchKit platform to tap millions of iPhone users to enroll in observational studies using apps

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs